Related Experiment Video
Updated: Aug 5, 2026
07:31
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
Metastases from single as compared to repeated tumour cell doses
Pathologia Europaea
|January 1, 1976
Summary
Tumour formation was studied using single or repeated intravenous tumour cell doses. Results showed minimal differences in tumour growth between dose schedules after reaching a critical cell dose.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Understanding tumourigenesis is crucial for developing effective cancer therapies.
- Investigating the impact of dosing schedules on tumour initiation provides insights into early cancer development.
Purpose of the Study:
- To investigate tumour formation following single versus repeated small intravenous tumour cell doses.
- To determine if dose scheduling affects tumourigenesis in a syngeneic model.
Main Methods:
- Utilized a syngeneic tumour-host system for preclinical cancer research.
- Administered single or repeated small intravenous doses of tumour cells.
- Monitored and compared tumour formation across different dose schedules.
Main Results:
- Tumour formation was observed from both single and repeated intravenous tumour cell administrations.
- Dose scheduling exhibited only marginal differences in tumourigenesis outcomes.
- A critical tumour cell dose level was identified, beyond which scheduling had minimal impact.
Conclusions:
- The timing of small intravenous tumour cell doses has a limited effect on tumour formation once a critical cell number is reached.
- These findings suggest that the total effective cell dose may be more critical than the administration schedule for tumour initiation in this model.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...